Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

Authors
Type
Published Article
Journal
Arthritis & Rheumatism
1529-0131
Publisher
Wiley Blackwell (John Wiley & Sons)
Publication Date
Volume
64
Issue
10
Pages
3156–3167
Identifiers
DOI: 10.1002/art.34627
PMID: 22806399
Source
Medline
License
Unknown

Abstract

Treatment with apremilast at a dosage of 20 mg twice per day or 40 mg once per day demonstrated efficacy in comparison with placebo and was generally well tolerated in patients with active PsA. The balance of efficacy, tolerability, and safety supports further study of apremilast in PsA.

Statistics

Seen <100 times